The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LUNG | -73.07% | -96.12% | -47.74% | -96% |
| S&P | +16.9% | +95.99% | +14.39% | +101% |
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, and Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $23.86M | 14.8% |
| Gross Profit | $17.10M | 11.7% |
| Gross Margin | 71.69% | -2.0% |
| Market Cap | $104.27M | -57.6% |
| Market Cap / Employee | $0.36M | 0.0% |
| Employees | 291 | 4.3% |
| Net Income | -$15.17M | 1.0% |
| EBITDA | -$14.41M | -6.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $75.73M | 18.8% |
| Accounts Receivable | $15.90M | 43.5% |
| Inventory | 16.2 | -4.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $55.61M | 1.1% |
| Short Term Debt | $1.22M | 4.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.61% | -4.0% |
| Return On Invested Capital | -29.80% | 2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.00M | 35.8% |
| Operating Free Cash Flow | -$3.96M | 31.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.49 | 2.85 | 3.12 | 1.34 | -39.73% |
| Price to Sales | 4.11 | 3.21 | 3.07 | 1.16 | -64.13% |
| Price to Tangible Book Value | 3.57 | 2.93 | 3.21 | 1.38 | -39.18% |
| Enterprise Value to EBITDA | -19.88 | -17.03 | -16.58 | -5.35 | -61.63% |
| Return on Equity | -52.0% | -55.3% | -60.7% | -66.9% | 35.89% |
| Total Debt | $55.81M | $56.47M | $56.95M | $56.83M | 1.14% |
LUNG earnings call for the period ending June 30, 2022.
LUNG earnings call for the period ending March 31, 2022.
LUNG earnings call for the period ending December 31, 2021.
LUNG earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
